Glyoxalase I Glu111Ala Polymorphism in Patients with Breast Cancer

• Published in: Cancer investigation Vol. 27; no. 6; pp. 655 - 660
• Main Authors: Germanová, Alexandra, Germanová, Anna, Tesarová, Petra, Jáchymová, Marie, Zvára, Karel, Zima, Tomáš, Kalousová, Marta
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01-01-2009; Taylor & Francis
• Subjects: Advanced glycation end products; Aged; AGEs; Breast cancer; Breast Neoplasms - enzymology; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Case-Control Studies; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Frequency; Genotype; Glycation End Products, Advanced - blood; Glyoxalase I; Humans; Lactoylglutathione Lyase - genetics; Middle Aged; Neoplasm Staging; Phenotype; Polymorphism, Single Nucleotide; Prognosis; Receptor for Advanced Glycation End Products; Receptors, Estrogen - analysis; Receptors, Immunologic - blood; Soluble receptor for advanced glycation end products; sRAGE
• ISSN: 0735-7907; 1532-4192
• DOI: 10.1080/07357900802350822

Effect of advanced glycation end products (AGEs) in the pathogenesis of cancer could be diminished by interaction with soluble RAGE or by reducing AGE-precursors via glyoxalase I. Glu111Ala polymorphism of glyoxalase I gene, AGEs, and sRAGE serum levels were studied in 113 breast cancer patients and in 58 controls. Higher frequency of the mutated C allele was found in patients with negative estrogen receptors and in patients in clinical stage III compared to controls (P< 0.05). The presence of the C allele could represent a negative prognostic factor; however, further studies are needed to confirm this hypothesis.